Royalty Pharma plc (RPRX) stock
Close on Nov 13, 2026Market cap $39.85BP/E 48.8Yield –
Royalty Pharma plc grew revenue 11.4% to $2.62B over the twelve months to Sep 30, 2026. Operating income fell 2.4% to $1.50B, moving the operating margin from 65.2% to 57.1%. At the latest close the market valued the company at $39.85B, 48.8 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $39.85B
- P/E ratio
- 48.8
- Price to sales
- 15.23
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $2.62B
- Net income
- $672.45M
- EPS, diluted
- $1.42
- Diluted shares
- 557M
Trading
- Next earnings
- Feb 10, 2027 (estimated, before the open)
- Previous close
- $68.97
- Open
- $68.77
- Day's range
- $68.14 – $69.42
- Volume
- 2,951,406
- Average volume (20 days)
- 3,410,802
- Index membership
- Russell 1000 (since Sep 2022)
- Beta (5 years)
- 0.41
- 52-week range
- $37.31 – $70.37
- RSI (14 days)
- 72.2
- Volatility (1 year)
- 22.1%
- Relative volume
- 0.96×
- WACC
- 7.2%
Index membership is inferred from the holdings of funds that track each index (IWB), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | RPRX | S&P 500 | Difference | RPRX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +22.9% | -3.0% | +26.0 pts | ||
| 3 months | +19.2% | -2.8% | +22.0 pts | ||
| Year to date | +82.5% | +11.5% | +71.0 pts | ||
| 1 year | +78.4% | +13.5% | +65.0 pts | ||
| 3 years | +177.0% | +77.7% | +99.3 pts | +40.4% | +21.1% |
| 5 years | +86.5% | +72.6% | +13.9 pts | +13.3% | +11.5% |
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Press releases
Releases Royalty Pharma filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Royalty Pharma
Pharmaceutical Preparations
Royalty Pharma acquires biopharmaceutical royalties and finances life sciences innovation. The company collaborates with academic institutions, non-profit organizations, biotechnology firms, and global pharmaceutical corporations across the biopharmaceutical development spectrum. Its primary offerings comprise third-party royalties on approved medicines, synthetic royalties created on late-stage candidates, and complementary capital arrangements including unsecured debt, equity investments, and launch funding. The company generates receipts from rights tied directly to end-market sales of commercial treatments across diverse therapeutic fields such as rare diseases, oncology, immunology, neuroscience, and respiratory care.
Company profile, executives and historyRoyalty Pharma stock: common questions
What is Royalty Pharma's stock price?
RPRX closed at $69.31 on Nov 13, 2026, up 0.49% on the day. Over the past 52 weeks it traded between $37.31 and $70.37.
What is Royalty Pharma's market cap?
Royalty Pharma was worth $39.85B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is RPRX's P/E ratio?
RPRX trades at 48.8 times earnings, based on diluted earnings per share of $1.42 over the twelve months to Sep 30, 2026.
How much revenue does Royalty Pharma make?
Royalty Pharma reported revenue of $2.62B for the twelve months to Sep 30, 2026, up 11.4% from a year earlier.
Does Royalty Pharma pay a dividend?
No. Royalty Pharma has not paid a cash dividend over the last twelve months.
When does Royalty Pharma report earnings next?
Royalty Pharma is expected to report Q4 FY2026 results on Feb 10, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has RPRX stock performed over the past year?
Including dividends, RPRX returned +78.4% over the past year, against +13.5% for the S&P 500.
How many RPRX shares are sold short?
13M shares were sold short at the latest FINRA report, 2.94% of the float, or 4.0 days of average trading volume.
Who are Royalty Pharma's competitors?
Companies most similar to Royalty Pharma by business, industry and size include SRPT, INSM, ALNY, BMRN, JAZZ.
See a number that looks wrong?